Biogen - Largest Companies by Marketcap, Revenue, Net Income and Employees
Top Corporates Hub
Biogen
BIIB
|
NASDAQ
|
United States
865
-305
Rank
$32.85B
Market Cap
$9.67B
-$ 0.16B
-1.63%
Revenue
$1.90B
+$ 0.61B
+47.29%
Earnings
7.6K
+0K
+0.46%
Employees
About
Biogen, Inc. (BIIB)
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
- Sector: Health Technology
- Industry: Pharmaceuticals: Major
- Headquarters:
Latest News
-
Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
09.07.2026 -
Biogen's Q2 2026 Earnings: What to Expect
09.07.2026 -
Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right Now
05.07.2026 -
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
04.07.2026 -
1 S&P 500 Stock with Promising Prospects and 2 We Question
02.07.2026